These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37839896)

  • 1. In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii, P. aeruginosa and Enterobacterales.
    Fouad A; Nicolau DP; Gill CM
    J Antimicrob Chemother; 2023 Dec; 78(12):2801-2809. PubMed ID: 37839896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
    Le Terrier C; Freire S; Nordmann P; Poirel L
    Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Yang Y; Guo Y; Yin D; Zheng Y; Wu S; Zhu D; Hu F
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139291
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Karlowsky JA; Hackel MA; McLeod SM; Miller AA
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0078122. PubMed ID: 36005804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China.
    Yang Q; Xu Y; Jia P; Zhu Y; Zhang J; Zhang G; Deng J; Hackel M; Bradford PA; Reinhart H
    J Antimicrob Chemother; 2020 Jul; 75(7):1833-1839. PubMed ID: 32306049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii.
    Seifert H; Müller C; Stefanik D; Higgins PG; Miller A; Kresken M
    J Antimicrob Chemother; 2020 Sep; 75(9):2616-2621. PubMed ID: 32516359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
    Turk Dagi H; Kus H; Arslan U; Tuncer I
    Mikrobiyol Bul; 2014 Apr; 48(2):311-5. PubMed ID: 24819268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates.
    Deveci A; Coban AY; Acicbe O; Tanyel E; Yaman G; Durupinar B
    J Chemother; 2012 Oct; 24(5):247-52. PubMed ID: 23182043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
    Zhao C; Xie W; Zhang W; Ye Z; Wu H
    Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections.
    Wareham DW; Momin MHFA; Phee LM; Hornsey M; Standing JF
    J Antimicrob Chemother; 2020 Jan; 75(1):135-139. PubMed ID: 31617905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter surveillance of
    Jean SS; Ko WC; Lu MC; Lee WS; Hsueh PR;
    Expert Rev Anti Infect Ther; 2022 Jun; 20(6):941-953. PubMed ID: 34933656
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    O'Donnell J; Tanudra A; Chen A; Miller AA; McLeod SM; Tommasi R
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0031223. PubMed ID: 38092676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant
    Petropoulou D; Siopi M; Vourli S; Pournaras S
    Front Cell Infect Microbiol; 2021; 11():814530. PubMed ID: 35127562
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    O'Donnell J; Tanudra A; Chen A; Newman J; McLeod SM; Tommasi R
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0080023. PubMed ID: 38092671
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
    Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
    Kaye KS; Shorr AF; Wunderink RG; Du B; Poirier GE; Rana K; Miller A; Lewis D; O'Donnell J; Chen L; Reinhart H; Srinivasan S; Isaacs R; Altarac D
    Lancet Infect Dis; 2023 Sep; 23(9):1072-1084. PubMed ID: 37182534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests.
    McLeod SM; Carter NM; Huband MD; Traczewski MM; Bradford PA; Miller AA
    J Clin Microbiol; 2024 Jan; 62(1):e0122823. PubMed ID: 38095417
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    McLeod SM; Moussa SH; Hackel MA; Miller AA
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988095
    [No Abstract]   [Full Text] [Related]  

  • 19. The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex.
    O'Donnell JP; Bhavnani SM
    Clin Infect Dis; 2023 May; 76(Suppl 2):S202-S209. PubMed ID: 37125469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres.
    Khan Z; Iregui A; Landman D; Quale J
    J Antimicrob Chemother; 2019 Oct; 74(10):2938-2942. PubMed ID: 31298277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.